Compare GSK plc (GSK) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kyndryl Holdings Inc — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while Kyndryl Holdings Inc trades at $11.83 (market cap $2.59B). The key difference: GSK plc is far larger — about 35.5× Kyndryl Holdings Inc's market cap, and GSK plc pays a 3.9% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Kyndryl Holdings Inc for 36 Days on average.
| GSK | KD | |
|---|---|---|
Market Cap | $91.88B | $2.59B |
Volume | 7,730,529 | 5,354,348 |
Sector | Health | Technology |
52-Week High | $61.18 | $29.76 |
52-Week Low | $43.24 | $10.59 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $111.88B | $5.41B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Kyndryl (KD) trades at $11.45, down 0.26% on the day, reflecting a challenging technical and fundamental environment. The stock exhibits a bearish technical signal with key support at $11 and resistance at $12, while recent earnings misses in Q4 2025 and Q1 2026 contrast with a beat in Q2 2026. Despite a low P/S ratio of 0.18 and positive net income of $252 million in 2025, the company's revenue has declined from $18.3B in 2022 to $15.1B in 2025. Recent news highlights a strategic focus on AI, including the launch of an innovation lab and the acquisition of Healthcare IT Leaders.
The outlook for KD is mixed, with a consensus price target of $14.67 suggesting potential upside, but analyst sentiment is cautious with 71% hold ratings. Key opportunities include AI-driven growth and improving profitability, while risks involve persistent revenue declines, high debt levels, and competitive pressures in the IT services sector. Execution on AI initiatives and future earnings performance will be critical for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
